GLP10 Antibody

GLP-1R Antibody Development Platforms

Modern antibody discovery employs advanced synthetic biology approaches:

• Phage display libraries enabled isolation of high-affinity GLP-1R binders (e.g., Glp1R0017) with species cross-reactivity (human, mouse, rat, cynomolgus monkey) .

• GPCR-focused synthetic libraries allowed engineering of antibodies with peptide-mimetic loops, achieving IC₅₀ values as low as 5.2 nM for cAMP inhibition .

• Structure-guided design facilitated creation of bispecific antibodies, such as TB-222-023, which showed superior antagonism compared to peptide inhibitors like exendin 9–39 .

Key GLP-1R Antibodies and Their Properties

Notable Features:

• TB-222-023: Demonstrated >90% receptor occupancy in pancreatic islets from pediatric patients with hyperinsulinism .

• Glp1R0017: Reduced glucose tolerance by 22% in oral glucose tolerance tests (OGTTs) in mice .

• Exenatide-conjugate: Achieved prolonged receptor activation via antibody-mediated half-life extension .

Functional Mechanisms and Signaling Pathways

GLP-1R antibodies exert effects through distinct pathways:

• Antagonists: Block GLP-1 binding, inhibiting cAMP production (↓80–95% at 10 nM) and insulin secretion in β-cells .

• Agonists: Mimic GLP-1 action via receptor crosslinking, enhancing insulin biosynthesis (↑300% in INS-1 cells) and β-cell survival .

• Immune modulation: Certain antibodies polarize macrophages toward anti-inflammatory M2 phenotypes, reducing IL-6 and TNF-α production by 40–60% .

Clinical and Preclinical Efficacy

Recent trials highlight therapeutic outcomes:

• TB-222-023: Achieved 72% faster glucose normalization versus placebo in diazoxide-resistant hyperinsulinism models .

• Glp1R0017: Reversed liraglutide-induced glucose lowering within 2 hours in intraperitoneal glucose tolerance tests (IPGTTs) .

• Survodutide (GCGR/GLP-1R agonist): Showed 20.9% placebo-subtracted weight loss in phase 3 obesity trials .

Comparative Advantages Over Peptide Therapeutics

Sources:

Challenges and Future Directions

• Species variability: Antibodies like Glp1R0017 require re-engineering for primate studies due to epitope divergence .

• Delivery optimization: Subcutaneous bioavailability remains <50% for full-length IgGs, necessitating formulation advances .

• Combination therapies: Co-administration with amylin analogs (e.g., cagrilintide) is under investigation to enhance weight loss efficacy .